SCHEMBL16131997

SCHEMBL16131997

Cc1ccc(CN2CCN(CCO)CC2)nc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 1/20 0.44
ALDH1A1 P00352 4/20 0.43
HRH3 Q9Y5N1 2/20 0.43
RAB9A P51151 2/20 0.43
KDM4E B2RXH2 2/20 0.43
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
GAA P10253 3/20 0.41
NPC1 O15118 1/20 0.41
TP53 P04637 1/20 0.41
POLB P06746 3/20 0.40
TSHR P16473 2/20 0.40
PKM P14618 1/20 0.40
KDM1A O60341 1/20 0.40
HPGD P15428 2/20 0.39
LMNA P02545 1/20 0.39
THRB P10828 1/20 0.39
ADRB2 P07550 1/20 0.39
GLA P06280 1/20 0.39
P4HB P07237 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12513 0.85 LTA4H (0.45) ALDH1A1HRH3KDM4EGAAPOLB
SCHEMBL7617880 0.82 ALDH1A1 (0.56) ALDH1A1HRH3RAB9AKDM4EMEN1
SCHEMBL12894384 0.82 HRH3 (0.53) ALDH1A1HRH3RAB9AKDM4ENPC1
SCHEMBL16132004 0.82 HRH3 (0.49) ALDH1A1HRH3RAB9AKDM4ENPC1
SCHEMBL15244569 0.81 HRH3 (0.43) CYP2C19ALDH1A1HRH3RAB9AKDM4E
SCHEMBL20071132 0.81 KCNH2 (0.39) ALDH1A1HRH3KDM4EPOLBTSHR
SCHEMBL13466407 0.81 ALDH1A1 (0.49) CYP2C19ALDH1A1HRH3RAB9AKDM4E
SCHEMBL12064 0.80 HRH3 (0.55) ALDH1A1HRH3RAB9AKDM4ENPC1
SCHEMBL15198044 0.78 HRH3 (0.57) HRH3
SCHEMBL12859199 0.78 DRD2 (0.59) ALDH1A1HRH3RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140288044-A1 COMPOSITIONS AND THERAPEUTIC USES OF IKK-RELATED KINASE EPSILON AND TANKBINDING KINASE 1 INHIBITORS ALZHEIMER'S INSTITUTE OF AMERICA, INC. (US) 2014-09-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140288044-A1 COMPOSITIONS AND THERAPEUTIC USES OF IKK-RELATED KINASE EPSILON AND TANKBINDING KINASE 1 INHIBITORS CSNK1G1, PRKCE, PHKG1 CYP2C19 4870/4885ALDH1A1 4487/4885HRH3 4523/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.